D-0731-2026 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Elmwood Park, NJ

FDA drug recall D-0731-2026 was initiated by Glenmark Pharmaceuticals Inc., USA on Jul 23, 2026 and is designated Class II. Reason for recall: CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received. The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Aug 5, 2026
Initiation Date
Jul 23, 2026
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by: Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ 07407, NDC 68462-626-52.

Reason for recall

CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

Distribution pattern

Nationwide within the United States.

Code information

Lot #: 19260937A, Exp. Date February 2028; 19261225A, 19261185A, Exp. Date March 2028; 19261664A, 19261682A, Exp. Date April 2028.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0731-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0731-2026. Report a data issue: hello@regdatalab.com.